[go: up one dir, main page]

EA200301299A1 - Применение ингибиторов il-18 для лечения и предотвращения повреждений цнс - Google Patents

Применение ингибиторов il-18 для лечения и предотвращения повреждений цнс

Info

Publication number
EA200301299A1
EA200301299A1 EA200301299A EA200301299A EA200301299A1 EA 200301299 A1 EA200301299 A1 EA 200301299A1 EA 200301299 A EA200301299 A EA 200301299A EA 200301299 A EA200301299 A EA 200301299A EA 200301299 A1 EA200301299 A1 EA 200301299A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
prevention
treatment
cns damage
damage
Prior art date
Application number
EA200301299A
Other languages
English (en)
Other versions
EA006744B1 (ru
Inventor
Эстер Шохами
Original Assignee
Арес Трейдинг С. А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арес Трейдинг С. А. filed Critical Арес Трейдинг С. А.
Publication of EA200301299A1 publication Critical patent/EA200301299A1/ru
Publication of EA006744B1 publication Critical patent/EA006744B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Данное изобретение относится к применению ингибиторов IL-18 в получении лекарственного препарата для лечения и/или предотвращения повреждения центральной нервной системы, в особенности травматического повреждения головы.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200301299A 2001-05-25 2002-05-23 Применение ингибиторов il-18 для лечения и предотвращения повреждений цнс EA006744B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01112067 2001-05-25
PCT/EP2002/005666 WO2002096456A1 (en) 2001-05-25 2002-05-23 Use of il-18 inhibitors for treating or preventing cns injuries

Publications (2)

Publication Number Publication Date
EA200301299A1 true EA200301299A1 (ru) 2004-04-29
EA006744B1 EA006744B1 (ru) 2006-04-28

Family

ID=8177454

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200301299A EA006744B1 (ru) 2001-05-25 2002-05-23 Применение ингибиторов il-18 для лечения и предотвращения повреждений цнс

Country Status (29)

Country Link
US (1) US7655616B2 (ru)
EP (1) EP1390070B1 (ru)
JP (1) JP4344142B2 (ru)
KR (1) KR20040030625A (ru)
CN (1) CN1305529C (ru)
AU (1) AU2002314103B2 (ru)
BG (1) BG66395B1 (ru)
BR (1) BR0210007A (ru)
CA (1) CA2445664C (ru)
CY (1) CY1119190T1 (ru)
CZ (1) CZ307321B6 (ru)
DK (1) DK1390070T3 (ru)
EA (1) EA006744B1 (ru)
EE (1) EE05263B1 (ru)
ES (1) ES2617084T3 (ru)
HR (1) HRP20030842B1 (ru)
HU (1) HU230294B1 (ru)
IL (2) IL159014A0 (ru)
LT (1) LT1390070T (ru)
ME (1) ME00550B (ru)
MX (1) MXPA03010743A (ru)
NO (1) NO331882B1 (ru)
PL (1) PL216228B1 (ru)
PT (1) PT1390070T (ru)
RS (1) RS56006B1 (ru)
SK (1) SK288413B6 (ru)
UA (1) UA80396C2 (ru)
WO (1) WO2002096456A1 (ru)
ZA (1) ZA200308172B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080076708A1 (en) 2003-05-13 2008-03-27 Valter Altarocca Active Variants of the Il-18 Binding Protein and Medical Uses Thereof
EP1780542A4 (en) * 2004-06-30 2008-05-14 Atsuo Sekiyama AGENT INDICATING A NON-INFLAMMATORY RESPONSE TO A STRESS AND USE THEREOF
DK1888100T3 (da) * 2005-06-03 2012-01-23 Merck Serono Sa Anvendelse af IL-18BP-isoformer til behandling og/eller forebyggelse af neurologiske inflammatoriske sygdomme
PL2267024T3 (pl) 2005-06-03 2012-10-31 Ares Trading Sa Wytwarzanie rekombinowanego białka wiążącego IL-18
HRP20110948T1 (hr) 2005-06-10 2012-01-31 Ares Trading S.A. Postupak za pročišćavanje il-18 vezujućeg proteina
US8685400B2 (en) * 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
AU2014317035B2 (en) * 2013-09-05 2020-02-27 Ab2 Bio Sa IL-18 binding protein (IL-18BP) in inflammatory diseases
SG11201706879UA (en) * 2015-03-05 2017-09-28 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0873453A (ja) * 1994-09-02 1996-03-19 Otsuka Pharmaceut Co Ltd サイトカイン阻害剤
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
ES2244178T3 (es) * 1998-03-09 2005-12-01 Vertex Pharmaceuticals Incorporated Derivados de 1,2-diazepan como inhibidores de la enzima convertidora de interleuquina-1 beta.
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
KR100798545B1 (ko) 2000-05-05 2008-01-28 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 죽상경화증의 치료 또는 예방을 위한 il-18 저해물질의용도
EP1292288B1 (en) * 2000-06-23 2004-09-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US6671553B1 (en) * 2001-05-23 2003-12-30 Pacesetter, Inc. Implantable cardiac lead having terminating connector strain relief and method of manufacture

Also Published As

Publication number Publication date
CZ20033268A3 (en) 2004-07-14
HK1069762A1 (en) 2005-06-03
IL159014A (en) 2012-05-31
HUP0304067A3 (en) 2006-01-30
CY1119190T1 (el) 2018-02-14
SK288413B6 (sk) 2016-10-03
YU89403A (sh) 2006-05-25
WO2002096456A1 (en) 2002-12-05
BR0210007A (pt) 2004-08-10
CA2445664A1 (en) 2002-12-05
NO20035160L (no) 2003-11-20
EP1390070B1 (en) 2017-02-08
RS56006B1 (sr) 2017-09-29
US7655616B2 (en) 2010-02-02
JP4344142B2 (ja) 2009-10-14
HUP0304067A2 (hu) 2004-03-29
KR20040030625A (ko) 2004-04-09
NO20035160D0 (no) 2003-11-20
PL367545A1 (en) 2005-02-21
PT1390070T (pt) 2017-03-01
DK1390070T3 (en) 2017-04-24
MXPA03010743A (es) 2004-03-02
SK16032003A3 (sk) 2004-05-04
ZA200308172B (en) 2004-10-21
CZ307321B6 (cs) 2018-06-06
BG108451A (en) 2005-02-28
CA2445664C (en) 2012-03-06
ES2617084T3 (es) 2017-06-15
PL216228B1 (pl) 2014-03-31
HU230294B1 (hu) 2015-12-28
EA006744B1 (ru) 2006-04-28
EE200300582A (et) 2004-02-16
EP1390070A1 (en) 2004-02-25
IL159014A0 (en) 2004-05-12
US20040191247A1 (en) 2004-09-30
JP2004534777A (ja) 2004-11-18
EE05263B1 (et) 2010-02-15
LT1390070T (lt) 2017-03-10
HRP20030842B1 (hr) 2017-06-02
CN1305529C (zh) 2007-03-21
ME00550B (me) 2011-10-10
AU2002314103B2 (en) 2007-07-12
AU2002314103B8 (en) 2002-12-09
BG66395B1 (bg) 2013-12-31
UA80396C2 (en) 2007-09-25
CN1535160A (zh) 2004-10-06
NO331882B1 (no) 2012-04-23
HRP20030842A2 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
CY1119190T1 (el) Χρηση αναστολεων της il-18 για αγωγη ή προληψη βλαβων του κνς
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
TR200200204T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
BR9812357A (pt) Tratamento de distúbio oposicional desafiador
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
PT1411926E (pt) Inibidores de integrina para o tratamento de doencas oftalmicas
EA200201175A1 (ru) Применение ингибиторов il-18 для лечения и/или предотвращения атеросклероза
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
DK1463735T3 (da) Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
CY1116137T1 (el) Χρηση των αναστολεων il-18 σε διαταραχες υπερευαισθησιας
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
ITMI20030573A1 (it) Composti ad azione nootropica, loro preparazione,
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
IL161116A0 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
MXPA04001205A (es) Compuesto para eliminar y/o mitigar la anhedonia.
TW200508196A (en) Hydroxamic acids useful in the treatment of hyper-proliferative disorders
BG101145A (bg) Използване на /s/-аденозил-l-метионин /саме/ i неговите физиологично съвместими соли за лечение нареперфузионно увреждане, причинено от временна фокална исхемиа
EE200300394A (et) GlyT-1 inhibiitorid
EA200500865A1 (ru) Синергетическая комбинация, включающая рофлумиласт и r,r-формотерол
EA200200750A1 (ru) Новое терапевтическое применение еноксапарина
WO2005065693A3 (en) Use of cathepsin z inhibitors for the treatment of rheumatoid arthritis and other autoimmune diseases

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM